© G.K.Raju, Ph.D. Confidential FDA Manufacturing Subcommittee Meeting July 20, 2004 G.K. Raju, Ph.D. Executive Director, MIT/PHARMI Massachusetts Institute.

Slides:

Advertisements

Similar presentations

Developing a Balanced Score Card Session 1 Viki Massey, Quality Coordinator A Joint Venture of London Health Sciences Centre and St. Josephs Health Care.

Advertisements

Life Science Services and Solutions

CONTINUOUS QUALITY VERIFICATION (CQV) G. K. Raju, Ph. D

The ACPS’s Process Analytical Technology Subcommittee

West Midlands Academic Health Science Network Mental Health Clinical Priority Event October 10 th, 2013 Peter Lewis Medical Director, Birmingham and Solihull.

Dr. Michael E. Oehlsen International Policy Analyst International Programs Team - Office of the Director Center for Veterinary Medicine Food and Drug Administration.

Strategic Development Council Press “Enter” or “click mouse” to continue through the presentation.

Perspectives on New Paradigms of Risk and Compliance in Pharmaceutical Development: Quality by Design, PAT, and Design Space David J. Cummings OPS Quality.

OPERATIONS and LOGISTICS MANAGEMENT

Manufacturing Subcommittee of the Advisory Committee for Pharmaceutical Science July 20-21, 2004 Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

Ray Scherzer FDA ACPS October 26, 2005 Breaking with Tradition: The Manufacturing Challenges Ahead!

MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.

MIS5102: Process Improvement and Innovation Course Introduction.

Challenges and Opportunities in Enhancement of the CMC Section of NDAs: Quality – by - Design Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical.

Final Report on Process Analytical Technology (PAT) and Manufacturing Science Ajaz S. Hussain, Ph.D. Deputy Director, Office of Pharmaceutical Science,

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.

FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.

Executive summary prepared by some members of the ICH Q9 EWG for example only; not an official policy/guidance July 2006, slide 1 ICH Q9 QUALITY RISK MANAGEMENT.

Achieving and Demonstrating “Quality-by-Design” with Respect to Drug Release/dissolution Performance for Conventional or Immediate Release Solid Oral Dosage.

Outline Thought for the day! Acknowledgements Top issues

D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.

ENTREPRENEURSHIP Lecture No: 27 Resource Person: Malik Jawad Saboor Assistant Professor Department of Management Sciences COMSATS Institute of Information.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.

© 2015 – Prax|Sage™ Inc … enabling synergistic collaboration, driving change.™

AHIMA & PHDSC A Transformational Alliance. CONFIDENTIAL AHIMA Background  Professional association founded in 1928 as the Association of Record Librarians.

Fostering a ‘Whole Community’ Approach to Emergency Management David J. Kaufman Director, Office of Policy and Program Analysis 8 June 2011.

1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

Managing Organisational Change Getting started: preparing your journey to implement transformational change.

© 2004 IBM Corporation Public Health Data Standards Consortium Panel March 17, 2004 Jill Kaufman, PhD. Program Director, Healthcare and Life Sciences Standards.

Laura Hibbs Head of Innovation, Knowledge and Intelligence 23 rd June 2014 Introduction to NHS Improving Quality.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Opening Remarks Ajaz S. Hussain, Ph.D.

Creating Collaborative Advantage and Developing Province-wide Research Capacity Presentation at Connect 2010 November 22, 2010.

10/11/ ENGINEERING RESEARCH CENTER FOR S TRUCTURED O RGANIC P ARTICULATE S YSTEMS RUTGERS UNIVERSITY PURDUE UNIVERSITY NEW JERSEY INSTITUTE OF TECHNOLOGY.

The International Society For Cellular Therapy. Mission Statement ISCT is a global association driving the translation of scientific research to deliver.

The Value Driven Approach

Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.

Office of Research iSTAR Initiative Update Debbie Flores 2/2009.

Progress in FDA’s Drug Product Quality Initiative Janet Woodcock, M.D. November 13, 2003.

FDA Regulation of Drug Quality: New Challenges Janet Woodcock, M.D. Director, Center for Drug Evaluation and Research, Food and Drug Administration November.

Pharmaceutical Manufacturing Subcommittee of the ACPS Ajaz S. Hussain, Ph.D. ACPS Meeting October 22, 2002.

Risk Sharing Schemes Dr Rafiq Hasan Director of Market Access

CDER / Office of Compliance ACPS October 5, 2006 Joseph C. Famulare Acting Deputy Director Office of Compliance CDER / FDA.

Second Meeting of the FDA/ACPS Process Analytical Technology: Closing Remarks Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Sciences.

FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.

Coalition Battle Management Language Study Group Dr. Michael Hieb Alion Science & Technology Major Kevin Galvin Ministry of Defence (UK), Directorate of.

Drug Quality Regulations for the 21 st Century PhRMA Perspective Manufacturing Subcommittee Meeting – May 21, 2003 Gerry Migliaccio Pfizer Inc.

Examining Drug Quality Regulation Douglas C. Throckmorton, MD Deputy Director Center for Drug Evaluation and Research Public Meeting on 21 CFR February,

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

© G.K.Raju, Ph.D. Manufacturing Science May 21st 2003 MANUFACTURING SCIENCE: The Means To GMPs In the 21 st Century.. G.K.Raju, Ph.D.

Career College Vision 2017 Career College the leaders in Allied Health Education.

1 Prepared by: Laila al-Hasan. 1. Definition of research 2. Characteristics of research 3. Types of research 4. Objectives 5. Inquiry mode 2 Prepared.

Generic Industry’s Perspective on the New GMP Initiative 2002 Generic Pharmaceutical Association Kenneth Lavin, M.Sc. Director, Regulatory Compliance TEVA.

© G.K.Raju, Ph.D. Manufacturing Science Sept 17th 2003 QUALITY BY DESIGN: The Means To Fundamental Manufacturing Science G.K.Raju, Ph.D.

South Big Data Innovation Hub

Ontario Health Coalition, Toronto, October 28, 2016

An Update on ICH Guideline – Pharmaceutical Development

Pharmaceutical Quality in the 21st Century

Developing a Balanced Score Card Session 1

Quality System.

Tuition Reimbursement Cap Waiver Proposal

QUALITY BY DESIGN Training Workshop on Pharmaceutical Development with focus on Paediatric Formulations Mumbai, India Date: May 2008.

Innovative Medicines Initiative:

Introduction to TransCelerate

Enterprise Architecture at Penn State

An Enabling Business Environment and A Strategic Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,

Industry Collaboration: A pilot study for developing a competency framework for Radiation Sterilization Professionals Arthur Dumba The Society for Sterility.

An Enabling Business Environment and A Strategy and Collaborative Approach for Sustainable Quality Local Production Africa Pharma Conference 4-5 June 2019,

Presentation transcript:

© G.K.Raju, Ph.D. Confidential FDA Manufacturing Subcommittee Meeting July 20, 2004 G.K. Raju, Ph.D. Executive Director, MIT/PHARMI Massachusetts Institute of Technology PHARMACEUTICAL MANUFACTURING IN THE 21 st CENTURY: A “Science” Perspective

© G.K.Raju, Ph.D. Confidential OUTLINE  THE “FRAME”  A VOCABULATORY  THE DESIRED STATE: “THERE”  THE CURRENT STATE: “HERE”  FROM “HERE” TO “THERE”: LEVERAGES  IMPLICATIONS  NEXT STEPS  ACKNOWLEDGEMENTS

© G.K.Raju, Ph.D. Confidential Pharmaceutical Manufacturing: A Social Capability Regulator Pharmaceutical Industry Patients Academia Government Pharma Mfg Health Care

© G.K.Raju, Ph.D. Confidential OUTLINE  INTRODUCTION  A “SCIENCE” PERSPECTIVE  THE DESIRED STATE: “THERE”  THE CURRENT STATE: “HERE”  FROM “HERE” TO “THERE”: LEVERAGES  IMPLICATIONS  NEXT STEPS  ACKNOWLEDGEMENTS

© G.K.Raju, Ph.D. Confidential “MANUFACTURING SCIENCE” : Mfg. Science LEVEL 1 LEVEL 2 LEVEL 4 LEVEL 5 LEVEL 3 CORRELATIVE KNOWLEDGE What Is Correlated to What? “CAUSAL" KNOWLEDGE What “Causes” What? MECHANISTIC KNOWLEDGE How? First Principles Why? DESCRIPTIVE KNOWLEDGE: What?

© G.K.Raju, Ph.D. Confidential A Science Perspective: 1. “SCIENCE” “Science” (noun) A body of knowledge, body of facts or information, body of laws or principles, body of truths, or verities or realities…… “Science” (a process) A means for solving problems…

© G.K.Raju, Ph.D. Confidential A “Science” Perspective: 2. MANUFACTURING “SYSTEM” A “manufacturing system” is a set of processes and systems (and people) bound by a common material and information flow. Material Information WEIGH WET GRANULN STEPFB DRY STEP BLEND ENCAPSULATE SIEVE QC 1 QC 3 QC 4 DRY MIX QC 2

© G.K.Raju, Ph.D. Confidential A “Science” Perspective: 3. Manufacturing “Capability” Voice of Your Customer Voice Of Your Process Manufacturing Capability = CEOScientistVP OperationsRegulatorPatient

© G.K.Raju, Ph.D. Confidential OUTLINE  INTRODUCTION  A “SCIENCE” PERSPECTIVE  THE DESIRED STATE: “THERE”  THE CURRENT STATE: “HERE”  FROM “HERE” TO “THERE”: LEVERAGES  IMPLICATIONS  NEXT STEPS  ACKNOWLEDGEMENTS

© G.K.Raju, Ph.D. Confidential “MANUFACTURING SCIENCE” : Desired State (“There”) Mfg. Science LEVEL 1 LEVEL 2 LEVEL 4 LEVEL 5 LEVEL 3 CORRELATIVE KNOWLEDGE What Is Correlated to What? “CAUSAL" KNOWLEDGE What “Causes” What? MECHANISTIC KNOWLEDGE How? First Principles Why? DESCRIPTIVE KNOWLEDGE: What?

© G.K.Raju, Ph.D. Confidential “PROCESS UNDERSTANDING”: THE DESIRED STATE Process Understanding Time LEVEL1 LEVEL2 LEVEL4 LEVEL5 LEVEL3 FDA Minimum Requirement Manufacturing Centric Approach to Manufacturing Science (“learning by doing”) Design/Development Centric Approach Manufacturing Science (“learning before doing”) Launch

© G.K.Raju, Ph.D. Confidential OUTLINE  INTRODUCTION  A “SCIENCE” PERSPECTIVE  THE DESIRED STATE: “THERE”  THE CURRENT STATE: “HERE”  FROM “HERE” TO “THERE”: LEVERAGES  IMPLICATIONS  NEXT STEPS  ACKNOWLEDGEMENTS

© G.K.Raju, Ph.D. Confidential “MANUFACTURING SCIENCE” : Current State (“Here”) Mfg. Science LEVEL 1 LEVEL 2 LEVEL 4 LEVEL 5 LEVEL 3 CORRELATIVE KNOWLEDGE What Is Correlated to What? “CAUSAL" KNOWLEDGE What “Causes” What? MECHANISTIC KNOWLEDGE How? First Principles Why? DESCRIPTIVE KNOWLEDGE: What?

© G.K.Raju, Ph.D. Confidential Time LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Process Understanding “PROCESS UNDERSTANDING”: THE CURRENT STATE (“HERE”)

© G.K.Raju, Ph.D. Confidential OUTLINE  INTRODUCTION  A “SCIENCE” PERSPECTIVE  THE DESIRED STATE: “THERE”  THE CURRENT STATE: “HERE”  FROM “HERE” TO “THERE”: LEVERAGES  IMPLICATIONS  NEXT STEPS  ACKNOWLEDGEMENTS

© G.K.Raju, Ph.D. Confidential FROM “HERE” TO “THERE”: STRATEGIC LEVERAGE Time LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Process Understanding What is “development”? Vocabulary? How do you measure? Knowledge to understanding

© G.K.Raju, Ph.D. Confidential FROM “HERE” TO “THERE”: TACTICAL LEVERAGE Time LEVEL1 LEVEL2 LEVEL 4 LEVEL5 LEVEL3 FDA Minimum Requirement Process Understanding Investigations True Root Causes Separate Critical From Non-critical

© G.K.Raju, Ph.D. Confidential OUTLINE  INTRODUCTION  A “SCIENCE” PERSPECTIVE  THE DESIRED STATE: “THERE”  THE CURRENT STATE: “HERE”  FROM “HERE” TO “THERE”: LEVERAGES  IMPLICATIONS  NEXT STEPS  ACKNOWLEDGEMENTS

© G.K.Raju, Ph.D. Confidential “SCIENCE” PERSPECTIVE: IMPLICATIONS 1. Finally, A Positive Vision ….. 2. Enabling Vocabulary

© G.K.Raju, Ph.D. Confidential “SCIENCE” PERSPECTIVE: IMPLICATIONS 3. Basis For VERY Different Relationship With Regulator Mfg. Science LEVEL 1 LEVEL 2 LEVEL 4 LEVEL 5 LEVEL 3 CORRELATIVE KNOWLEDGE What Is Correlated to What? “CAUSAL" KNOWLEDGE What “Causes” What? MECHANISTIC KNOWLEDGE How? First Principles Why? DESCRIPTIVE KNOWLEDGE: What? Lower Risk Quality By Design More Harmonized Lower Cost High Quality Lower Times

© G.K.Raju, Ph.D. Confidential  cGMPS FOR 21 st CENTURY  Science Based  Risk Based  Modern Quality Management Techniques  Harmonization  PAT – A FRAMEWORK FOR INNOVATIVE PHARMACEUTICAL MANUFACTURING AND QUALITY ASSURANCE “SCIENCE” PERSPECTIVE: IMPLICATIONS 4. Connectivity to Current Momentum

© G.K.Raju, Ph.D. Confidential “SCIENCE” PERSPECTIVE: IMPLICATIONS 5. A Basis To Collaborate With Your “Competitor” Mfg. Science LEVEL 1 LEVEL 2 LEVEL 4 LEVEL 5 LEVEL 3 CORRELATIVE KNOWLEDGE What Is Correlated to What? “CAUSAL" KNOWLEDGE What “Causes” What? MECHANISTIC KNOWLEDGE How? First Principles Why? DESCRIPTIVE KNOWLEDGE: What?

© G.K.Raju, Ph.D. Confidential “SCIENCE” PERSPECTIVE: IMPLICATIONS 6. An Inside-Out View That Enables A Systems View Regulator Pharmaceutical Industry Patients Academia Government Pharma Mfg Health Care

© G.K.Raju, Ph.D. Confidential “SCIENCE” PERSPECTIVE: IMPLICATIONS 7. A Foundation To Transform Lives All Over Again.. Time Last 25 Years 2028 Next 25 Years Last 25 Years 2028 Next 25 Years A New Shared Vision Manufacturing Capability

© G.K.Raju, Ph.D. Confidential Time Social Resources Required “Ensure” Last 25 Years 2028 Next 25 Years A New Shared Vision Time To Quality Last 25 Years 2028 Next 25 Years A New Shared Vision “Science” Perspective: 7. A Foundation To Transform Lives All Over Again

© G.K.Raju, Ph.D. Confidential OUTLINE  INTRODUCTION  A “SCIENCE” PERSPECTIVE  THE DESIRED STATE: “THERE”  THE CURRENT STATE: “HERE”  FROM “HERE” TO “THERE”: LEVERAGES  IMPLICATIONS  NEXT STEPS  ACKNOWLEDGEMENTS

© G.K.Raju, Ph.D. Confidential NEXT STEPS  Broaden Shared Vision  Long Term Social Roadmap  A “Real” Economic Case  “Real” Case Studies  “Pilot” The Future

© G.K.Raju, Ph.D. Confidential OUTLINE  INTRODUCTION  A “SCIENCE” PERSPECTIVE  THE DESIRED STATE: “THERE”  THE CURRENT STATE: “HERE”  FROM “HERE” TO “THERE”: LEVERAGES  IMPLICATIONS  NEXT STEPS  ACKNOWLEDGEMENTS

© G.K.Raju, Ph.D. Confidential ACKNOWLEDGEMENTS l Consortium For The Advancement Of Manufacturing Of Pharmaceuticals (CAMP) l Charles Cooney (MIT) l Steve Byrn and Kenneth Morris (PURDUE) l Janet Woodcock, Helen Winkle and Ajaz Hussain (FDA)